Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$154.54
-0.3%
$159.48
$140.68
$169.99
$371.83B0.497.90 million shs8.64 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$884.94
+2.9%
$827.69
$677.09
$972.53
$839.07B0.513.43 million shs3.40 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$62.07
-0.9%
$73.62
$57.00
$148.15
$278.54B0.616.09 million shs7.83 million shs
Novartis AG stock logo
NVS
Novartis
$112.23
+1.0%
$109.68
$96.06
$120.92
$237.08B0.561.54 million shs2.21 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%-1.83%-5.56%+1.07%+5.75%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+5.14%+7.88%+9.50%+20.64%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+7.04%-10.50%-29.02%-51.07%
Novartis AG stock logo
NVS
Novartis
0.00%+1.39%-0.41%+8.57%+15.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.6862 of 5 stars
3.33.04.23.93.42.50.6
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9178 of 5 stars
3.45.03.34.02.72.51.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.555 of 5 stars
4.13.02.50.02.10.04.4
Novartis AG stock logo
NVS
Novartis
2.3009 of 5 stars
2.03.02.50.02.80.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.56
Moderate Buy$171.8211.18% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.89
Moderate Buy$1,017.0014.92% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.25
Hold$135.00117.50% Upside
Novartis AG stock logo
NVS
Novartis
2.00
Hold$123.389.93% Upside

Current Analyst Ratings Breakdown

Latest NVS, LLY, NVO, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Dbs Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSell
4/22/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$975.00
4/17/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.00
4/17/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/17/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$105.00 ➝ $64.00
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.00
4/15/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy ➝ Underperform
4/15/2025
Novartis AG stock logo
NVS
Novartis
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/14/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.00
(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$89.33B4.16$12.70 per share12.17$29.69 per share5.21
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B18.63$14.43 per share61.34$15.05 per share58.80
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B0.96$2.88 per share21.57$4.64 per share13.38
Novartis AG stock logo
NVS
Novartis
$51.72B4.58$11.19 per share10.03$21.59 per share5.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$8.9923.2413.962.5618.20%34.24%13.63%7/16/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7175.5728.441.4023.51%85.24%16.19%5/1/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2918.8713.320.9034.81%84.68%26.29%5/7/2025 (Estimated)
Novartis AG stock logo
NVS
Novartis
$11.94B$5.8819.0912.741.7023.56%37.24%15.85%4/29/2025 (Estimated)

Latest NVS, LLY, NVO, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92N/AN/AN/A$79.17 billionN/A
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
4/29/2025Q1 2025
Novartis AG stock logo
NVS
Novartis
$2.07N/AN/AN/A$12.92 billionN/A
4/15/2025Q1 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
1/31/2025Q4 2024
Novartis AG stock logo
NVS
Novartis
$1.80$1.98+$0.18$1.41$12.86 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.203.36%+5.43%57.84%64 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.68%+15.21%51.24%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.632.63%+25.26%49.54%N/A
Novartis AG stock logo
NVS
Novartis
$2.592.31%+5.34%44.05%N/A

Latest NVS, LLY, NVO, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.37%5/27/20255/27/20256/10/2025
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
2/20/2025
Novartis AG stock logo
NVS
Novartis
$3.86953/12/20253/12/20253/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.43
1.11
0.86
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55
Novartis AG stock logo
NVS
Novartis
0.48
1.04
0.84

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Novartis AG stock logo
NVS
Novartis
13.12%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Novartis AG stock logo
NVS
Novartis
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
152,7002.41 billion2.40 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable
Novartis AG stock logo
NVS
Novartis
101,7002.11 billion2.04 billionOptionable

Recent News About These Companies

Analysts Set Novartis AG (NYSE:NVS) Price Target at $123.38

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$154.54 -0.39 (-0.25%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$154.26 -0.28 (-0.18%)
As of 04/25/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$884.94 +25.21 (+2.93%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$886.55 +1.61 (+0.18%)
As of 04/25/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$62.07 -0.56 (-0.89%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$62.10 +0.03 (+0.05%)
As of 04/25/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis stock logo

Novartis NYSE:NVS

$112.23 +1.06 (+0.95%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$106.62 -5.62 (-5.00%)
As of 04/25/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.